The main thrust of the proposed research is to combine the advantages of ultrasonic drug delivery and micellar drug carriers into a novel technology that will deliver high local concentrations of drugs to tissues exposed to localized acoustic energy. Ultrasound is non-invasive, can be carefully controlled and focused on the target tissue; it induces drug release from micelles and enhances the intracellular drug uptake and it can simultaneously create a hyperthermic condition. Micellar drug carriers prevent unwanted drug interaction with healthy tissues while sensitizing multidrug resistant (MDR) cells to the action of drugs. The foundation of this proposal is the hypothesis that micellar drug delivery combined lwith ultrasonic activation can target drugs to tumors, enhance the cytotoxicity of drugs in sensitive and MDR tumors, and suppress tumor growth.
Specific aims of the project include: 1. To extend a panel of /cell fines, drugs, and polymeric micelles for which the above technology may prove beneficial, In particular, to include taxol into the panel of drugs since it has low solubility in commonly used media and low activity in multidrug resistant cells. The cytotoxicity of Doxorubicin (DOX) and taxol in vitro will be measured in A2780 ovarian carcinoma, MCF7 breast cancer, and P388 leukemia cell lines (both dwg-sensitive and MDR), and in DHD/KlZ/TRb colon cancer cell line. 2. To test the hypothesis that micelfar drug delivery combined with ultrasound suppresses tumor growth in vivo and increases survival rates of tumor-bearing mice. Experiments will be performed with drug-sensitive and MDR A2780 and MCF7 tumors grown subcutaneously, and P388 internal tumors grown in the peritoneal cavity of mice; micellar-encapsutated DOX and taxol will be delivered with and without 20-kHz ultrasound applied to the tumors at various duty cycles and power densities. 3. To extend and scale up in vivo experiments using the DHDMZFRb colon cancer model in rats. Experiments will be performed with micellar encapsulated DOX combined with 20-kHz and 70-kHz ultrasound. All three specific aims are focused on clinically relevant targets.
|Gupta, Roohi; Shea, Jill; Scafe, Courtney et al. (2015) Polymeric micelles and nanoemulsions as drug carriers: Therapeutic efficacy, toxicity, and drug resistance. J Control Release 212:70-7|
|Thakkar, Dhaval; Gupta, Roohi; Monson, Kenneth et al. (2013) Effect of ultrasound on the permeability of vascular wall to nano-emulsion droplets. Ultrasound Med Biol 39:1804-11|
|Thakkar, Dhaval; Gupta, Roohi; Mohan, Praveena et al. (2012) Overcoming Biological Barriers with Ultrasound. AIP Conf Proc 1481:381-387|
|Rapoport, Natalya (2012) Phase-shift, stimuli-responsive perfluorocarbon nanodroplets for drug delivery to cancer. Wiley Interdiscip Rev Nanomed Nanobiotechnol 4:492-510|
|O'Neill, Brian E; Rapoport, Natalya (2011) Phase-shift, stimuli-responsive drug carriers for targeted delivery. Ther Deliv 2:1165-87|
|Rapoport, Natalya; Nam, Kweon-Ho; Gupta, Roohi et al. (2011) Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsions. J Control Release 153:4-15|
|Shea, Jill E; Nam, Kweon-Ho; Rapoport, Natalya et al. (2011) Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma. HPB (Oxford) 13:153-7|
|Rapoport, Natalya; Christensen, Douglas A; Kennedy, Anne M et al. (2010) Cavitation properties of block copolymer stabilized phase-shift nanoemulsions used as drug carriers. Ultrasound Med Biol 36:419-29|
|Mohan, Praveena; Rapoport, Natalya (2010) Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking. Mol Pharm 7:1959-73|
|Rapoport, Natalya; Kennedy, Anne M; Shea, Jill E et al. (2010) Ultrasonic nanotherapy of pancreatic cancer: lessons from ultrasound imaging. Mol Pharm 7:22-31|
Showing the most recent 10 out of 19 publications